Clinical Trials Logo

Clinical Trial Summary

Rationale: 20-30% of women of reproductive age have leiomyomas, causing symptoms like dysmenorrhea and pelvic pain which both effect quality of life.[1-4] The natural behaviour of uterine fibroids is to grow between 7 to 84% in 3 to 12 months.[5-7] Non-surgical options to treat uterine fibroids are non-hormonal or hormonal medical therapies and minimally invasive interventional radiologic techniques. Exogenous hormone exposure including COC, POP or Mirena give in conflicting literature minimal growth to 60% volume shrinkage. [8, 9]] Selective progesterone receptor modulators (SPRM) eg. Esmya and GnRH-analogues intent to reduce fibroids volume after several months; GnRH-agonists provide a 31-63% shrinkage and less frequently applied GnRH-antagonists 14.3 - 42.7%.[10-16] Esmya gives a volume reduction varying between 10 to 48%.[17] Radiological technique like embolization decreases dominant fibroid volume with 40-70%.[1, 18-22] UAE fails in case of devascularized or minimal vascularized fibroids.[23] Ablation techniques show shrinkage up to a maximum of 90% depending e.g. which treatment.[24-41] Clear prognostic models to predict the effect on fibroid related symptoms and volume reduction are lacking. We postulate higher vascularity to be related to 1) larger fibroid growth during the natural course or during exogenous hormonal exposure; 2) more effective shrinkage during progestogens, GnRH-analogues, SPRM and UAE; but 3) less effective after ablation therapy. Objectives: To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRM or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy. Study design: Observational cohort study during 5 years in the outpatient clinic. Patientselection: Women ≥18 years with 1 to 3 fibroids with a maximal diameter ≥ 3cm and ≤ 10cm diagnosed on ultrasound examination, planned for expectant or non-surgical management. Study objectives: The primary outcome is volume reduction after 3 to 12 month depending on the study group. The secondary outcome include UFS-QOL, EQ-5D score, PBAC, hemoglobin level, treatment failure rate and (re)intervention rate. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: No risks are associated with the participation of this observational study since the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are also applied in daily practice, the burden for the patient is time. Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05741671
Study type Observational
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Judith Huirne, Prof.
Phone 0031205664167
Email j.huirne@amsterdamumc.nl
Status Recruiting
Phase
Start date September 24, 2018
Completion date September 2023

See also
  Status Clinical Trial Phase
Completed NCT00152256 - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids Phase 3
Recruiting NCT04145518 - Mechanistic Characterization of Uterine Pain Phase 4
Completed NCT05419414 - The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis N/A
Recruiting NCT04272086 - Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy Phase 4
Completed NCT00156156 - Study of Asoprisnil in the Treatment of Uterine Fibroids. Phase 3
Recruiting NCT06269809 - Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial N/A
Recruiting NCT06429163 - Pre-incisional Wound INfiltration and Hypogastric PLEXus Block Using Ropivacaine in Laparoscopic Myomectomy N/A
Recruiting NCT04295109 - Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function N/A
Not yet recruiting NCT04250766 - Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors (BIOPSAR) N/A
Terminated NCT02879058 - Intraoperative Ultrasound in Laparoscopic or Robotic Myomectomy Patients N/A
Recruiting NCT04311073 - Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies Phase 3
Recruiting NCT06143631 - Prescription of Letrozole for Uterine Myoma Phase 4
Completed NCT03927651 - ICG to Assess Ovarian Perfusion Early Phase 1
Recruiting NCT03550703 - Open Label Immunotherapy of Myoma Phase 2
Completed NCT00910468 - Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids N/A
Recruiting NCT05518812 - Carboprost (Hemabate) for Fibroid Resection Early Phase 1
Recruiting NCT03757975 - Impact of Hysterectomy on Quality of Life and Urethral Length
Active, not recruiting NCT04434066 - Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy N/A
Recruiting NCT05017246 - Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy Phase 2
Completed NCT05643339 - The Reproducibility of Microvascular Flow Imaging in Fibroids and Its Correlation With 2D and 3D Power Doppler Outcomes